CDK4 inhibitors an emerging strategy for the treatment of melanoma

about

Cell Cycle Regulation and Melanoma.

P2860

Q38815527-57119DB0-0032-4C74-B792-241F5E3550E9

P2860

CDK4 inhibitors an emerging strategy for the treatment of melanoma

Item

http://www.wikidata.org/entity/Q57571832

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2015

@uk

name

CDK4 inhibitors an emerging strategy for the treatment of melanoma

@en

CDK4 inhibitors an emerging strategy for the treatment of melanoma

@nl

type

Item

label

CDK4 inhibitors an emerging strategy for the treatment of melanoma

@en

CDK4 inhibitors an emerging strategy for the treatment of melanoma

@nl

prefLabel

CDK4 inhibitors an emerging strategy for the treatment of melanoma

@en

CDK4 inhibitors an emerging strategy for the treatment of melanoma

@nl

P1476

CDK4 inhibitors an emerging strategy for the treatment of melanoma

@en

P2860

A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells

A landscape of driver mutations in melanoma

The lab oddity prevails: discovery of pan-CDK inhibitor (R)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the treatment of cancer

Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.

Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Cancer statistics, 2013

Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers

Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma

P304

255-266

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/MMT.15.14

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Grant McArthur

Belinda Lee

P577

2015-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30190853

http://www.w3.org/2001/XMLSchema#string

P932

6094902

http://www.w3.org/2001/XMLSchema#string

CDK4 inhibitors an emerging strategy for the treatment of melanoma

about

P2860

P2860

CDK4 inhibitors an emerging strategy for the treatment of melanoma

description

name

type

label

prefLabel

P1433

P1476

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932